Enavatuzumab

Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the TWEAK receptor.[1]

Enavatuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetTWEAK receptor
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6334H9792N1700O2000S42
Molar mass143104.43 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Enavatuzumab was developed by Facet Biotech Corp.[2]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.